GR agonists(Glucocorticoid receptor agonists), cPLA2α agonists(Cytosolic phospholipase A2 agonists), β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists)

Therapeutic Areas

Immune System DiseasesRespiratory Diseases

Active Indication

Airway ObstructionAsthmaPulmonary Disease, Chronic Obstructive

Inactive Indication

Bronchitis, ChronicEmphysemaIntermittent asthma

Originator Organization

GSK Plc

Active Organization

Intech Biopharm Ltd.

Glaxo Group Ltd.

Teva Pharmaceutical Industries Ltd.

+ [9]

Inactive Organization

Mylan Pharma UK Ltd.

Drug Highest PhaseApproved

First Approval Date

US (24 Aug 2000),

AsthmaPulmonary Disease, Chronic Obstructive

Regulation-

Structure

Molecular FormulaC25H31F3O5S

InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N

CAS Registry80474-14-2

View All Structures (2)

261

Clinical Trials associated with Fluticasone propionate/Salmeterol xinafoate

NCT06676319 / RecruitingPhase 2

A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment

This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma.
The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig compared with placebo in male and female participants (aged 18 to 80 years, inclusive) with asthma, who are not currently eligible for biologic treatments.
Study details include:
* The study duration will be approximately 64 weeks for participants not transitioning into the LTS study and approximately 60 weeks for participants transitioning into the LTS study.
* The investigational treatment duration will be up to approximately 52 weeks.
* The number of visits will be 18.

Start Date07 Nov 2024

Sponsor / Collaborator

Sanofi

NCT06572228 / RecruitingPhase 4

AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma

This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe. Uncontrolled asthma means that patients are still having frequent symptoms while taking their current asthma medication.
The aim of the study is to see which regimen is more effective: taking dupilumab with an inhaled asthma medication or only taking a higher dose of the inhaled asthma medication. The type of asthma medication that will be used is a combination inhaled corticosteroid and long-acting beta-agonist (referred to as an ICS/LABA). Some patients may also receive an additional asthma medication called a long-acting muscarinic antagonist (referred to as a LAMA) if they are already receiving a LAMA.
The study is also looking at:
• What side effects may happen from taking dupilumab

Start Date26 Aug 2024

Sponsor / Collaborator

Regeneron Pharmaceuticals, Inc.

[+1]

CTR20241130 / CompletedNot Applicable

沙美特罗替卡松吸入粉雾剂在中国成年健康受试者中的一项单中心、随机、开放、空腹单次给药生物等效性试验

[Translation] A single-center, randomized, open-label, fasting single-dose bioequivalence study of salmeterol/fluticasone inhalation powder in healthy Chinese adult subjects

主要研究目的：考察空腹状态下单次经口吸入受试制剂沙美特罗替卡松吸入粉雾剂与参比制剂沙美特罗替卡松吸入粉雾剂在中国健康人体的相对生物利用度，比较两制剂药代动力学特征，评估两制剂的生物等效性。次要研究目的：评价空腹状态下使用受试制剂和参比制剂在中国成年健康受试者中的安全性。

[Translation]

The main purpose of the study is to investigate the relative bioavailability of the test preparation salmeterol-fluticasone inhalation powder and the reference preparation salmeterol-fluticasone inhalation powder in healthy Chinese subjects after single oral inhalation in the fasting state, to compare the pharmacokinetic characteristics of the two preparations, and to evaluate the bioequivalence of the two preparations. Secondary purpose of the study is to evaluate the safety of the test preparation and the reference preparation in healthy Chinese adult subjects in the fasting state.

Start Date05 Jun 2024

Sponsor / Collaborator

Aitme (Suzhou) Medical Technology Co., Ltd.

100 Clinical Results associated with Fluticasone propionate/Salmeterol xinafoate

100 Translational Medicine associated with Fluticasone propionate/Salmeterol xinafoate

100 Patents (Medical) associated with Fluticasone propionate/Salmeterol xinafoate

659

Literatures (Medical) associated with Fluticasone propionate/Salmeterol xinafoate

01 Nov 2024·JOURNAL OF NUTRITION

Excess Folic Acid Exposure Increases Uracil Misincorporation into DNA in a Tissue-Specific Manner in a Mouse Model of Reduced Methionine Synthase Expression

Article

Author: Brody, Lawrence C ; Malysheva, Olga V ; Malysheva, Olga V. ; Brody, Lawrence C. ; Field, Martha S. ; Field, Martha S ; Heyden, Katarina E ; MacFarlane, Amanda J ; Heyden, Katarina E. ; MacFarlane, Amanda J.

BACKGROUND:

Folate and vitamin B12 (B12) are cofactors in folate-mediated 1-carbon metabolism (FOCM), a metabolic network that supports synthesis of nucleotides (including thymidylate [dTMP]) and methionine. FOCM impairments such as a deficiency or imbalance of cofactors can perturb dTMP synthesis, causing uracil misincorporation into DNA.

OBJECTIVE:

The purpose of this study was to determine how reduced expression of the B12-dependent enzyme methionine synthase (MTR) and excess dietary folic acid interact to affect folate distribution and markers of genome stability in mouse tissues.

METHODS:

Heterozygous Mtr knockout mice (Mtr^+/-) model the FOCM-specific effects of B12 deficiency. Folate accumulation and vitamer distribution, genomic uracil concentrations, and phosphorylated histone H2AX (γH2AX) immunostaining were measured in male Mtr^+/+ and Mtr^+/- mice weaned to either a folate-sufficient control (C) diet (2 mg/kg folic acid) or a high folic acid (HFA) diet (20 mg/kg folic acid) for 7 wk.

RESULTS:

Exposure to the HFA diet led to tissue-specific patterns of folate accumulation, with plasma, colon, kidney, and skeletal muscle exhibiting increased folate concentrations compared with control. Liver total folate did not differ. Although unmetabolized folic acid (UMFA) increased 10-fold in mouse plasma with HFA diet, UMFA accounted for <0.2% of total folate in liver and colon tissue. Exposure to HFA diet resulted in a shift in folate distribution in colon tissue with higher 5-methyl-THF and lower formyl-THF than in control mice. Mtr heterozygosity did not impact folate accumulation or distribution in any tissue. Mice on HFA diet exhibited higher uracil in genomic DNA and γH2AX foci in colon. Similar differences were not seen in liver.

CONCLUSIONS:

This study demonstrates that folic acid, even when consumed at high doses, does not meaningfully accumulate in mouse tissues, although high-dose folic acid shifts folate distribution and increases uracil accumulation in genomic DNA in colon tissue.

01 Oct 2024·PHARMACEUTICAL RESEARCH

Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques

Article

Author: Price, Robert ; Newman, Bryan ; Mangal, Sharad ; Ganley, William J. ; Bielski, Elizabeth ; Farias, Gonçalo ; Conti, Denise S. ; Shur, Jagdeep ; Conti, Denise S ; Ganley, William J

Abstract:

Purpose:

For locally-acting dry powder inhalers (DPIs), developing novel analytical tools that are able to evaluate the state of aggregation may provide a better understanding of the impact of material properties and processing parameters on the invivo performance. This study explored the utility of the Morphologically-Directed Raman Spectroscopy (MDRS) and dissolution as orthogonal techniques to assess microstructural equivalence of the aerosolized dose of DPIs collected with an aerosol collection device.

Methods:

Commercial DPIs containing different strengths of Fluticasone Propionate (FP) and Salmeterol Xinafoate (SX) as monotherapy and combination products were sourced from different regions. These inhalers were compared with aerodynamic particle size distribution (APSD), dissolution, and MDRS studies.

Results:

APSD testing alone might not be able to explain differences reported elsewhere in invivo studies of commercial FP/SX drug products with different Advair® strengths and/or batches. Dissolution studies demonstrated different dissolution rates between Seretide™ 100/50 and Advair® 100/50, whereas Flixotide™ 100 and Flovent® 100 had similar dissolution rates between each other. These differences in dissolution profiles were supported by MDRS results: the dissolution rate is increased if the fraction of FP associated with high soluble components is increased. Principle component analysis was used to identify the agglomerate classes that better discriminate different products.

Conclusions:

MDRS and dissolution studies of the aerosolized dose of DPIs were successfully used as orthogonal techniques. This study highlights the importance of further assessing invitro tools that are able to provide a bridge between material attributes or process parameters and invivo performance.

01 Sep 2024·International Orthodontics

Shear bond strength of orthodontic brackets to single-shade composite surfaces: An in-vitro comparative study of different surface preparations

Article

Author: Dupree, Peter ; Mon, Htwe ; Ballard, Richard W ; Chapple, Andrew ; Armbruster, Paul ; Xu, Xiaoming ; Rathel, Hayden

PURPOSE:

The primary objective of this study was to determine which single-shade composite surface yielded clinically acceptable shear bond strength (SBS) to metal orthodontics brackets. The secondary objectives were to identify the best composite surface treatment to enhance SBS and determine which surface treatment produced the least surface damage at debond.

METHODS:

Forty dental composite samples were selected from four different manufacturers (n=160) and grouped by manufacturer, one standard multi-shade dental system (FilTek™ Supreme Ultra) and three single-shade dental composites systems (OmniChroma®, SimpliShade™ and Venus® Diamond One). Each group of forty samples was randomly divided into four sub-groups (n=10). Each sub-group was identified by the surface treatment used, hydrofluoric acid (HFA), micro-etching (MIC), or phosphoric acid (PA). Shear bond strength testing and adhesive remnant index (ARI) were performed. Statistical analyses included Kruskal-Wallis, Wilcoxon rank-sum, and two-factorial ANOVA.

RESULTS:

OmniChroma® had statistically significant lower shear bond strength than the other composite materials tested. The control groups had statistically significant lower shear bond strength than Group 1/HFA (P<0.001) and Group 2/MIC (P<0.001). Group 1/HFA had the lowest distribution ARI score overall, while MIC had the highest ARI score distributions.

CONCLUSIONS:

The results of this in-vitro study found that all tested composite materials achieved clinically acceptable shear bond strengths. The utilization of micro-etching produced higher SBS. Significant Adhesive Remnant Index scores (< 0.001) were only found for OmniChroma® without any surface preparation.

News (Medical) associated with Fluticasone propionate/Salmeterol xinafoate

12 Nov 2024

·www.prnewswire.com

Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight

After over a decade without notable progress in treating chronic obstructive pulmonary disease, patients with this ongoing condition now have two new treatment options, with more expected in the future. Regeneron and Sanofi recently revealed that the FDA has expanded the approved uses of their widely successful drug DUPIXENT to include COPD treatment. This marks the drug's sixth approved indication in the US, following its first approval seven years ago for atopic dermatitis. LAS VEGAS, Nov. 12, 2024 /PRNewswire/ -- Chronic obstructive pulmonary disease (COPD) is a progressive lung condition characterized by obstructed airflow, making breathing difficult. It primarily encompasses two main conditions: chronic bronchitis and emphysema, often coexisting. COPD typically develops due to long-term exposure to irritants such as cigarette smoke, air pollution, or occupational dust. As per DelveInsight analysis, the diagnosed prevalent population of COPD in the 7MM was around 44 million in 2023. These cases of COPD in the 7MM are expected to increase at a significant CAGR of 1.4% throughout the study period (2020–2034). As per the estimates, the majority of cases of COPD are in females as compared to males, in the US. But in EU4 and the UK, and Japan the diagnosed cases of males represent the majority of the cases. Overall, in the 7MM, females are predominantly high in number. In 2023, the US had around 3 million, 9 million, 5 million, and 1 million cases of GOLD 1, GOLD 2, GOLD 3, and GOLD 4, respectively based on the severity of airflow limitation. Estimates suggest that airflow limitation was higher in GOLD 2 severity. Various types of medications are used to manage COPD symptoms and complications, including bronchodilators, which help relax the muscles around the airways. This relaxation opens the airways and makes breathing easier. Most bronchodilators are administered via an inhaler. In more severe cases, the inhaler may also contain steroids to reduce inflammation. Some commonly used short-acting and long-acting bronchodilators for COPD management include Albuterol (ProAir HFA, Ventolin HFA, and others), Ipratropium (Atrovent HFA), Levalbuterol (Xopenex), Aclidinium (Tudorza Pressair), Arformoterol (Brovana), and Formoterol (Perforomist). In the LABA category, medications such as Striverdi Respimat, Arcapta/Onbrez, Serevent, and Brovana are included, while the LAMA class features drugs like Spiriva (available as Spiriva HandiHaler and Spiriva Respimat), Tudorza Pressair, Incruse Ellipta, Yupelri, Seebri Neohaler, and Lonhala Magnair. Since the generic version of Brovana was approved in April 2020, its market share has declined. Additionally, Arcapta Neohaler, Seebri Neohaler, and Utibron Neohaler were discontinued in the US in March 2020, which means they no longer contribute to market size. Patients who do not respond to single therapies are often prescribed double or triple therapy. Among the double therapies, the LABA+ICS combination is widely recommended, with drugs such as Symbicort, Breo Ellipta, and Advair. There are also LABA+LAMA combinations, including Anoro Ellipta, Stiolto Respimat, and Bevespi Aerosphere. In July 2020, the US FDA approved AstraZeneca's BREZTRI AEROSPHERE for the maintenance treatment of patients with COPD. Additionally, in October 2020, TRIXEO AEROSPHERE (a combination of formoterol fumarate, glycopyrronium bromide, and budesonide) received marketing authorization in the EU for the maintenance treatment of adult patients with moderate to severe COPD who are not adequately controlled by either a combination of an ICS and LABA or a LABA and LAMA. Currently, two triple combination therapies are available in the US: BREZTRI and TRELEGY ELLIPTA. Learn more about the FDA-approved COPD drugs @ Drugs for COPD Treatment Recently, Sanofi/Regeneron Pharmaceuticals' DUPIXENT added one more jewel to its crown by getting a label expansion nod for COPD from the FDA, EU, and NMPA. DUPIXENT's approval as the first targeted therapy for COPD represents a significant advancement in the treatment landscape for the disease. Unlike conventional treatments, which largely aim to manage symptoms, DUPIXENT specifically targets the IL-4 and IL-13 pathways linked to type 2 inflammation, a key driver in a subset of COPD patients. This precision in targeting allows for a more tailored treatment, especially for patients with elevated eosinophils, who often experience more frequent exacerbations and worse outcomes. The Phase III BOREAS trial demonstrated that patients treated with DUPIXENT experienced a 30% reduction in moderate-to-severe exacerbations over 52 weeks, significant improvements in lung function, and enhanced quality of life. By Week 52, those on DUPIXENT had improved prebronchodilator FEV1 by 160 mL compared to 77 mL in the placebo group. DUPIXENT was also well-tolerated, with a low frequency of adverse events. These results suggest that DUPIXENT could drastically shift COPD management by reducing exacerbations, improving lung function, and offering a safer, targeted therapy for patients with type 2 inflammation. To know more about COPD treatment options, visit @ New Treatment for COPD The chronic obstructive pulmonary disease pipeline possesses potential drugs in mid-stage developments to be launched in the near future. Itepekimab (Sanofi/Regeneron Pharmaceuticals), Benralizumab (AstraZeneca), Tezepelumab (Amgen/AstraZeneca), Mepolizumab (GSK), and others shall further create a positive impact on the market. Discover which therapies are expected to grab major COPD market share @ COPD Market Report Itepekimab is a fully human monoclonal antibody that targets interleukin-33 (IL-33), a protein involved in both type 1 and type 2 inflammation. The drug is administered via subcutaneous injection. Preclinical studies demonstrated that REGN3500 effectively inhibited several markers of both inflammatory types. Regeneron and Sanofi are investigating REGN3500 in diseases related to respiratory and dermatological inflammation. Currently, REGN3500 is in a Phase III clinical trial for COPD and was developed using Regeneron's VelocImmune technology, which produces optimized fully human antibodies. The development is part of a global collaboration between Regeneron and Sanofi. FASENRA (benralizumab) is a humanized recombinant monoclonal antibody of the IgG1k immunoglobulin type that selectively targets the alpha chain of the interleukin 5 receptor (IL-5R) found on eosinophils and basophils. It prevents IL-5 from binding and stops the hetero-oligomerization of the IL-5R's alpha and beta subunits, thereby inhibiting signal transduction. Additionally, it is an afucosylated IgG, which enhances its affinity for the FcγRIIIα receptor on natural killer cells, macrophages, and neutrophils. Approved by the FDA in November 2017 for severe eosinophilic asthma, benralizumab was developed by MedImmune, AstraZeneca's global biologics R&D division. The company is currently conducting Phase III clinical trials for FASENRA as a treatment for COPD. TEZSPIRE (tezepelumab), a pioneering human monoclonal antibody created by Amgen and AstraZeneca, has shown considerable therapeutic potential for various respiratory conditions. Originally intended for treating COPD, TEZSPIRE has yielded encouraging results in decreasing moderate-to-severe exacerbations in patients with high blood eosinophil counts. Recent findings from the Phase IIa COURSE Trial, unveiled at the ATS 2024 conference, underscored TEZSPIRE's effectiveness in minimizing COPD exacerbations among patients with different eosinophil levels. Mepolizumab is currently undergoing Phase III clinical trials for COPD, particularly in patients with frequent exacerbations and elevated eosinophil levels. It is available as an injectable solution and a powder for reconstitution for subcutaneous administration. The IL-5 receptor complex activates several signaling pathways that lead to the release of cytokines, neuromediators, chemokines, and various kinases, which facilitate eosinophil differentiation, proliferation, recruitment, and degranulation. Mepolizumab works by inhibiting the formation of the IL-5 receptor complex, thereby preventing eosinophil activation. This disruption affects normal eosinophil maturation and function, leading to decreased eosinophilic airway inflammation and reduced eosinophil survival. Discover more about drugs for COPD in development @ COPD Clinical Trials The anticipated launch of these emerging therapies for COPD are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the COPD market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for COPD in the 7MM is expected to grow from USD 16 billion in 2023 with a significant CAGR of 5% by 2034. This growth is mainly driven by the rise in the number of prevalent cases of COPD, ongoing clinical research, and better diagnostic tools that might improve the prognosis of the disease. DelveInsight's latest published market report titled as Chronic Obstructive Pulmonary Disease Market Insight, Epidemiology, and Market Forecast – 2034 will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the COPD country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The COPD market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Diagnosed Prevalent Cases of COPD Subtype-specific Diagnosed Prevalent Cases of COPD Gender-specific Diagnosed Prevalent Cases of COPD Age-specific Diagnosed Prevalent Cases of COPD Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM COPD market. Highlights include: 11-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this COPD market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the COPD market. Also, stay abreast of the mitigating factors to improve your market position in the COPD therapeutic space. Related Reports Chronic Obstructive Pulmonary Disease Pipeline Chronic Obstructive Pulmonary Disease Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key COPD companies, including Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, Immunotek, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., Tetherex Pharmaceutical, CSL Behring, AstraZeneca, Novartis, Genentech, Vertex Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Foresee Pharmaceuticals, Amgen, Organicell Regenerative Medicine, Arrowhead Pharmaceuticals, ProterixBio, RS BioTherapeutics, MitoRx, C4X Discovery, Respiratorius, ARK biosciences, Incannex, GNI Pharma, Celon pharma, Alveolus Bio, Kinaset therapeutics, Landos Biopharma, Parion Sciences, KeyMed Biosciences, Bioneer corporation, AlgiPharma, Palobiofarma, Dimerix Bioscience, Glenmark Pharmaceuticals, among others. Asthma Market Asthma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key asthma companies including GlaxoSmithKline, 4D Pharma plc, AstraZeneca, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Sinomab, Avalo Therapeutics, Kymab, Sanofi, Cumberland Pharmaceuticals, Genentech, Inc. , among others. Asthma Pipeline Asthma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key asthma companies, including Jiangsu Hengrui Medicine, GlaxoSmithKline, Immunotek SL, AB Science, EMS, Avalo Therapeutics, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., ARS Pharmaceuticals, Sanofi, Zura Bio Ltd., AstraZeneca, EURRUS Biotech GmbH, T-Balance Therapeutics GmbH, Gossamer Bio, Aldeyra Therapeutics, Inc., Trio Medicines, Janssen Research & Development, Arrowhead Pharmaceuticals, Hoffman-La-Roche, GlaxoSmithKline, Biohaven Pharmaceutical, TAK-Circulator Co., Shanghai Hengrui Pharmaceutical, among others. Acute Respiratory Distress Syndrome Market Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ARDS companies, including MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultDrug ApprovalPhase 3Phase 2

30 Jul 2024

·www.fiercepharma.com

South Korea regulator hits GSK for problems with asthma, acne drugs: report

South Korea’s Ministry of Food and Drug Safety penalized GSK for failing to inform the agency of a change in API specifications in certain asthma meds. South Korea’s Ministry of Food and Drug Safety issued a pair of administrative penalties to GSK for manufacturing and labeling problems on certain asthma and acne treatments, Korea Biomedical Review reports.In its rebuke of GSK, the regulatory agency said the company violated regulations by failing to report changes it made to the APIs used to make Seretide 100 Discus (fluticasone-salmeterol), Seretide 250 Discus, Seretide 500 Discus, and Flixotide Junior Evohaler 50, according to KBR. The drugs are used to treat asthma.The company was also scolded for confusing manufacturing numbers and expiration dates on its labels for acne drug Duacgel 5% (clindamycin phosphate-containing benzoyl peroxide), according to the publication. As part of its action, the agency imposed a 15-day sales suspension from Aug. 1 to 15 on Duacgel 5%, according to KBR.GSK was fined 52.2 million won ($37,680) on Seretide 100 Discus, Seretide 250 Discus, and Seretide 500 Discus. GSK was also hit with a six-month import suspension on Flixotide Junior Evohaler 50mcg that runs from Aug. 1, 2024, to Jan. 31, 2025.Fierce reached out to GSK for comment on the regulatory action.

Drug Approval

08 Aug 2023

·www.drugs.com

Generic, Brand-Name Medication Similarly Effective for COPD

MONDAY, Aug. 7, 2023 -- For patients with chronic obstructive pulmonary disease (COPD), generic and brand-name fluticasone-salmeterol are similarly effective and safe, according to a study published online Aug. 8 in the Annals of Internal Medicine . William B. Feldman, M.D., D.Phil., from Brigham and Women's Hospital in Boston, and colleagues compared the effectiveness and safety of generic (Wixela Inhub) and brand-name (Advair Diskus) fluticasone-salmeterol among patients with COPD in a propensity score-matched cohort study. Of 27,305 Advair Diskus users and 18,064 Wixela Inhub users, 10,012 matched pairs were included in the primary analysis. The researchers found that Wixela Inhub use was associated with a nearly identical incidence of first moderate or severe COPD exacerbation compared with Advair Diskus (hazard ratio, 0.97; 95 percent confidence interval, 0.90 to 1.04) and with a similar incidence of first pneumonia hospitalization (hazard ratio, 0.99; 95 percent confidence interval, 0.86 to 1.15). "In patients with COPD, the generic inhaled corticosteroid-long-acting β-agonist Wixela Inhub had nearly identical effectiveness and safety when compared with brand-name Advair Diskus," the authors write. "Similar studies can provide a useful means of evaluating the clinical effectiveness and safety of complex generic products after approval." Abstract/Full Text (subscription or payment may be required) Posted August 2023

Clinical Result

100 Deals associated with Fluticasone propionate/Salmeterol xinafoate

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	R03AK06	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Airway Obstruction	US	Glaxo Group Ltd.	30 Apr 2008
Asthma	US	Glaxo Group Ltd.	24 Aug 2000
Pulmonary Disease, Chronic Obstructive	US	Glaxo Group Ltd.	24 Aug 2000

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bronchitis, Chronic	Phase 3	JP	GSK Plc	28 Jan 2005
Emphysema	Phase 3	JP	GSK Plc	28 Jan 2005
Intermittent asthma	Phase 2	NZ	GSK Plc	01 Mar 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04677959 (CONNECT2, CTgov)	Phase 4	Asthma	427	Albuterol+Fluticasone propionate/salmeterol (FS)	yxfrxsgsxd(aiyixhovfp) = hxrmxyglax ohapejryzv (qwivvmseji, khwmwrviep - fgzkxvbeye) View more	-	14 Mar 2023
ERS2022	Not Applicable	Pulmonary Disease, Chronic Obstructive Maintenance	195	Budesonide/Formoterol MART	cdlslcoceh(tpeyprpjee) = Similar proportions of patients reported adverse events (Budesonide/Formoterol MART: 73% vs Fluticasone/Salmeterol fixed-dose therapy: 68%, p=0.41) ameauusjwt (ojuwpsqyjq ) View more	-	04 Sep 2022
				Fluticasone/Salmeterol fixed-dose therapy
NCT03219866 (CTgov)	Phase 4	Pulmonary Disease, Chronic Obstructive \| Disease Progression	40	Nebulizers+Pulmicort+Brovana+Atrovent (Nebulizers)	ctvbrtrsdd(pojulniebd) = gzzzaaqkjn brnmalsvzm (xjjqgihtjz, iwmduwmldt - lhmnkhhhlu) View more	-	10 Jun 2021
				Dry Powder Inhaler+Spiriva HandiHaler+Advair Diskus (Dry Powder Inhaler)	ctvbrtrsdd(pojulniebd) = ebqxjzstgd brnmalsvzm (xjjqgihtjz, wewjyfcogd - tokfkiluzg) View more
NCT02245672 (Pubmed)	Phase 3	Asthma	1,127	Wixela Inhub	stkzvxvtmu(oalxvybbaf) = zkdqxoqcek xkbjmemuom (zuxxbntbgw ) View more	-	01 Apr 2020
				Advair Diskus	stkzvxvtmu(oalxvybbaf) = yvskgyuabl xkbjmemuom (zuxxbntbgw ) View more
NCT02980133 (CTgov)	Phase 3	Persistent asthma	841	Fluticasone Propionate (Fp MDPI 25 mcg BID)	cfwxvhallv(vgwydvfqcg) = iuxakcwqvz pgjgsdsktz (otfalyimvi, aiqdheusia - oyqosfwewq) View more	-	18 Mar 2020
				Fluticasone Propionate (Fp MDPI 50 mcg BID)	cfwxvhallv(vgwydvfqcg) = lsbflgdptd pgjgsdsktz (otfalyimvi, lgdeuwjezx - lwfnfcqier) View more
NCT02924688 (CAPTAIN, CTgov)	Phase 3	Asthma	2,436	VI+Fluticasone Furoate+Vilanterol+salbutamol (FF/VI 100/25 mcg)	gnwrgqmtff(qzofxmiypd) = injdijtbqi dwubritpvd (qyxxzfjdcu, kcyigbgldc - xiiaebwofg) View more	-	21 Feb 2020
				VI+Fluticasone Furoate+Vilanterol+albuterol+Umeclidinium (FF/UMEC/VI 100/ 31.25/25 mcg)	gnwrgqmtff(qzofxmiypd) = zeuppxvosz dwubritpvd (qyxxzfjdcu, uapjhfltle - gnsknffvng) View more
NCT02251379 (ECATCh, CTgov)	Phase 2	Childhood asthma	155	Home Environmental Intervention+Flovent Diskus+Advair Diskus (ECS + Medication Group)	orxoltkrdz(pdqljgbccb) = pkpjnwipbz jwbircscqk (fyelpuqitv, bvbodedcih - wpywyykfjk) View more	-	04 Nov 2019
				Flovent Diskus+Advair Diskus (Medication Group Alone)	orxoltkrdz(pdqljgbccb) = ugtwtmizuu jwbircscqk (fyelpuqitv, dvzhwwzlbd - zzroxoflcg) View more
NCT03167541 (CTgov)	Phase 1	-	18	Naproxen Sodium (Test: RB Naproxen Sodium 2 x 220 mg)	ejjjpgjwyk(jixnnwfrgr) = gojrbbdjwu mmskwtwptu (kgloeinxuc, hskybafskr - awptkgghcf) View more	-	28 Feb 2019
				Naproxen Sodium (Reference: Aleve Naproxen Sodium 2x220 mg)	ejjjpgjwyk(jixnnwfrgr) = qbyjymadhu mmskwtwptu (kgloeinxuc, ylbiqhglox - dwcerelltv) View more
NCT02424539 (CTgov)	Phase 4	Perennial allergic rhinitis with seasonal variation	358	placebo (Placebo)	lfgdyepgur(ecxcgwhnvc) = vvwmghhbji ikiknkpbnn (wpehiaukqm, ygfpvyqudp - bmsejaveqi) View more	-	06 Feb 2019
				FF (FF 55 µg QD)	lfgdyepgur(ecxcgwhnvc) = htefvoaive ikiknkpbnn (wpehiaukqm, kwggliugeo - tawkuzrzej) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis